State Street SPDR S&P Pharmaceuticals ETF
$62.10−1.91 (−2.98%)
- 0.35%
- $469M
- +35.9%
- 0.43%
- 0.1M sh
- $64.69
- low $46.90high $74.35
The ETF.net XPH Grade
B
Score 67 out of 100
- 2 of 9
Score 67 of 100 falls in the B band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.
Cost
The fund’s net expense ratio, ranked against its category.A79 out of 100Rank 2 of 9Mission
Whether the fund did what it promised, tested against its stated mandate.B62 out of 100Rank 6 of 6Risk
How the fund held up when markets fell: downside volatility, drawdowns and tail loss.C42 out of 100Rank 6 of 9Tradability
How easy the fund is to trade: daily volume, and how far its price strays from net asset value.B61 out of 100Rank 5 of 9Holdings
How concentrated the fund is, and how complete and current its disclosed holdings are.A89 out of 100Rank 1 of 9Durability
Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.B69 out of 100Rank 4 of 9
Our read on XPH
BMost pharma funds are a mega-cap sandwich. XPH equal-weights instead, so a small-cap drugmaker gets roughly the same say as an industry giant, across about 60 names, for 0.35% a year.
The fund seeks to provide exposure to the pharmaceuticals segment of the S&P TMI.
Why people hold it
- Modified equal weighting with quarterly rebalances: the index trims what has run and keeps real room for small and mid-cap drugmakers, not just the household names.ssga.com
- At 0.35%, the cheapest sticker in its pharma peer group and well under the group median of 0.57% (PPH 0.36%, IHE 0.37%, PJP 0.57%, FTXH 0.60%).
- Pure pharma, not a health care grab bag: it draws only from the pharmaceuticals segment of the S&P Total Market Index. No insurers, hospitals or device makers.ssga.com
- Running since 2006 under a single index rulebook, with assets in the mid-size range and about 60 holdings behind it.
Worth knowing
- Equal weighting pulls the portfolio down the cap ladder, where trial results and FDA decisions can swing a single stock hard. Expect a bumpier ride than mega-cap pharma.ssga.com
- One industry, one country. Drug pricing rules and patent cliffs hit the whole basket at once.
- Moderately traded rather than a volume monster, so spreads can widen. Limit orders are the usual answer.
XPH Holdings
- Stocks
- 64
- 23%
- XERS
Sectors
- Health Care100.0%
Geography
- United States96.09%
- Ireland3.91%
XPH Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
XPH$13,591
Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | XPH |
|---|---|
| Year to date | +14.6% |
| 1 month | −5.1% |
| 3 months | −6.4% |
| 1 year | +35.9% |
| 3 years | +20.2% |
| 5 years | +7.5% |
| 10 years | +5.1% |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | XPH |
|---|---|---|
| 2026 YTD | +14.6% | |
| 2025 | +31.6% | |
| 2024 | +4.9% | |
| 2023 | +3.0% | |
| 2022 | −9.8% | |
| 2021 | −10.5% | |
| 2020 | +14.7% |
XPH in the news
XPH Dividends
- 0.43%
- $0.27
- $0.04 per share
- Quarterly
Distribution history
XPH Risk
- 20.4%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.74
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −30.9%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.72
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
XPH Cost
0.35%
XPH0.35%
- The middle half of Pharma & Therapeutics funds
- Median 0.58%
1 of the 9 Pharma & Therapeutics funds charge less.
Other funds in Pharma & Therapeutics
- APPHVanEck Pharmaceutical ETFExpense ratio 0.36%1 year return +22.6%
- BIHEiShares U.S. Pharmaceuticals ETFExpense ratio 0.37%1 year return +37.5%
- BPJPInvesco Pharmaceuticals ETFExpense ratio 0.58%1 year return +34.5%
- BPBPHPortfolio Building Block World Pharma and Biotech Index ETFExpense ratio 0.13%1 year return —
- BFTXHFirst Trust Nasdaq Pharmaceuticals ETFExpense ratio 0.60%1 year return +43.8%